NCT01760642View on ClinicalTrials.gov

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Healthy
Interventions
DRUG

Midazolam

Midazolam 3 mg IV

DRUG

Ketoconazole

ketoconazole 400 mg PO

DRUG

Rifampicin

Rifampicin 600 mg PO

Trial Locations (1)

110-744

Seoul National Universtiy Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT01760642 - Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity | Biotech Hunter | Biotech Hunter